Abstracts tagged "Disease Activity"

Abstract Number: 1760 • 2018 ACR/ARHP Annual Meeting
Fungal Composition of the Nasal Mucosa in Patients with Granulomatosis with Polyangiitis
Rennie L. Rhee¹, Antoine G. Sreih¹, Catherine E. Najem², Peter C. Grayson³, Chunyu Zhao⁴, Kyle Bittinger⁴, Ronald Collman⁵ and Peter A. Merkel⁶, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Rheumatology, University of Pennsylvania, Philadelphia, PA, ³National Institute of Arthritis, Musculoskeletal and Skin Disease, National Institutes of Health, Bethesda, MD, ⁴Gastroenterology, Hepatology, and Nutrition, Children's Hospital of Philadelphia, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: While prior studies have demonstrated that granulomatosis with polyangiitis (GPA; Wegener’s) is associated with an altered composition of nasal bacteria and that use of…
Abstract Number: 2209 • 2018 ACR/ARHP Annual Meeting
Fluorescence Optical Imaging Xiralite® Is Helpful in the Decision for Rituximab Re-Therapy in Patients with Rheumatoid Arthritis
Sarah Ohrndorf¹, Lisa Ridha², Anne-Marie Glimm³, Gerd R. Burmester¹, Gabriela Schmittat³, Marina Backhaus⁴ and Jens Klotsche⁵, ¹Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Berlin, Germany, ²Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany, ³Department of Rheumatology and Clinical Immunology, Charité University Medicine Berlin, Berlin, Germany, ⁴Department of Rheumatology & Immunology, University Medicine Charit, Berlin, Germany, ⁵Program Area Epidemiology, German Rheumatism Research Center, Berlin, Germany
Background/Purpose: Rituximab (RTX) is an effective and well-tolerated therapeutic option in rheumatoid arthritis (RA) patients with insufficient response to TNFα inhibitors. However, the exact time…
Abstract Number: 2590 • 2018 ACR/ARHP Annual Meeting
Descriptive Comparisons of the Impact of Apremilast and Methotrexate Monotherapy in Patients with Oligoarticular Psoriatic Arthritis in the Corrona Psoriatic Arthritis/Spondyloarthritis Registry
Alexis Ogdie¹, Mei Liu², Meghan Glynn², Kelechi Emeanuru², Leslie R Harrold³, Sven Richter⁴, Benoit Guerette⁴ and Philip J. Mease⁵, ¹University of Pennsylvania, Philadelphia, PA, ²Corrona, LLC, Waltham, MA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Celgene Corporation, Summit, NJ, ⁵Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: The effectiveness of therapies has rarely been studied in the subpopulation of patients with oligoarticular psoriatic arthritis (PsA). The objective of this study was…
Abstract Number: 2916 • 2018 ACR/ARHP Annual Meeting
New JADAS10- and cJADAS10-Based Cutoffs for Juvenile Idiopathic Arthritis Disease Activity States: Validation in a Multinational Dataset of 4830 Patients
Alessandro Consolaro^1,2, Chiara Trincianti¹, Pieter van Dijkhuizen³, Giedre Januskeviciute⁴, Gabriella Giancane⁵, Alessandra Alongi¹, Joost Swart³, Nicola Ruperto^6,7 and Angelo Ravelli^2,8, ¹University of Genova, Genova, Italy, ²Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genova, Italy, ³UMC Utrecht, Wilhelmina Children’s Hospital, Utrecht, Netherlands, ⁴Istituto Giannina Gaslini, Genova, Italy, ⁵Clinica Pediatrica - Reumatologia, Istituto Giannina Gaslini, Genoa, Italy, ⁶Universita di Genova Pediatria II, Genova, Italy, ⁷Paediatric Rheumatology International Trials Organisation (PRINTO), Genoa, Italy, ⁸University of Genova, Genoa, Italy
Background/Purpose: The Juvenile Arthritis Disease Activity Score (JADAS) and its clinical version excluding the acute phase reactant (cJADAS) were developed for measuring disease activity in…
Abstract Number: 214 • 2018 ACR/ARHP Annual Meeting
Exploring the Relation between Air Pollution and Disease Activity in Patients with Rheumatoid Arthritis
Tommaso Schioppo¹, Valentina Bollati^2,3, Chiara Favero^2,3, Nicola Ughi¹, Isabella Scotti¹, Valeria Merlino¹, Orazio De Lucia¹, Antonella Murgo¹ and Francesca Ingegnoli^1,3, ¹Division of Clinical Rheumatology, G. Pini Hospital, Milan, Italy, ²EPIGET Lab, Milan, Italy, ³Dept. of Clinical Sciences & Community Health, Università degli Studi di Milano, Milan, Italy
Background/Purpose: Disease remission is considered an achievable target in a significant proportion of patients with rheumatoid arthritis (RA). Nevertheless, diseases flares, that significantly contributes to…
Abstract Number: 548 • 2018 ACR/ARHP Annual Meeting
Persistence in Low Disease Activity or Remission with Etanercept Monotherapy in Patients with Rheumatoid Arthritis: Results from the Corrona Registry
Dimitrios A. Pappas¹, Ying Shan², Tamara Lesperance³, Sabrina Rebello², Elaine Karis⁴, Greg Kricorian⁴, Winnie Hua⁵, Neil A. Accortt⁴ and Scott Stryker⁴, ¹Corrona LLC, Waltham, MA, ²Corrona, LLC, Southborough, MA, ³DOCS Global, Inc., North Wales, PA, ⁴Amgen Inc., Thousand Oaks, CA, ⁵Corrona, LLC, Waltham, MA
Background/Purpose: Monotherapy with etanercept (ETN) may be a viable therapeutic option for maintenance of patients with rheumatoid arthritis (RA) who prefer to eliminate potential burdens…
Abstract Number: 1093 • 2018 ACR/ARHP Annual Meeting
Serologic Evidence Linking Epstein Barr Virus Reactivation, Heightened Interferon Pathway Activation and Increased Disease Activity in Patients with Systemic Lupus Erythematosus
Rebecca Wood¹, Lauren Guthridge¹, Carla J. Guthridge², Rebecka L. Bourn¹, Hua Chen¹, Wade DeJager¹, Susan R. Macwana¹, Stan Kamp¹, Rufei Lu^1,3, Cristina Arriens¹, Eliza Chakravarty¹, Katherine Thanou¹, Joan T. Merrill¹, Joel M. Guthridge^1,4 and Judith A. James^4,5, ¹Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Medicine and Pathology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is a clinically heterogeneous disease oftentimes characterized by a waxing and waning course. Mechanisms of SLE flare remain elusive. This study examined relationships…
Abstract Number: 1598 • 2018 ACR/ARHP Annual Meeting
Depression and Anxiety Reduce Probability of Achieving a State of Minimal Disease Activity in Patients with Psoriatic Arthritis
Antonio Wong Lam¹, Justine Y. Ye², Dafna D Gladman¹ and Vinod Chandran², ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Depression and/or anxiety are comorbidities associated with psoriatic arthritis (PsA) that may affect treatment response. We aimed to determine whether the presence of depression/anxiety…
Abstract Number: 1762 • 2018 ACR/ARHP Annual Meeting
Plasma iC3b Level As a Biomarker of Disease Relapse in ANCA-Associated Vasculitis
Catherine E. Najem¹, Martin Schmidt², Chad Stiening³, David Cuthbertson⁴, Simon Carette⁵, Nader A. Khalidi⁶, Curry L. Koening⁷, Carol Langford⁸, Carol A. McAlear⁹, Paul A. Monach¹⁰, Larry W. Moreland¹¹, Christian Pagnoux¹², Philip Seo¹³, Ulrich Specks¹⁴, Antoine G. Sreih¹, Steven R. Ytterberg¹⁵ and Peter A. Merkel^16,17, ¹Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Kypha, Inc., St. Louis, MO, ³Kypha, Inc., St Louis, MO, ⁴Biostatistics and Informatics, Department of Pediatrics, Department of Biostatistics and Informatics, Department of Pediatrics, University of South Florida, Tampa, FL, ⁵Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ⁶Rheumatology, McMaster University, Hamilton, ON, Canada, ⁷Rheumatology, Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁸Rheumatic and Immunologic Diseases, Department of Rheumatic and Immunologic Diseases, Cleveland Clinic, Cleveland, OH, ⁹Division of Rheumatology, University of Pennsylvania; Perelman School of Medicine, Philadelphia, PA, ¹⁰Section of Rheumatology, Boston University School of Medicine, Boston, MA, ¹¹Division of Rheumatology and Clinical Immunology, Division of Rheumatology, University of Pittsburgh, Pittsburgh, PA, ¹²Division of Rheumatology, Division of Rheumatology, Mount Sinai Hospital, Toronto, ON, Canada, ¹³Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ¹⁴Mayo Clinic College of Medicine, Rochester, MN, ¹⁵Rheumatology, Division of Rheumatology, Mayo Clinic College of Medicine, Rochester, MN, ¹⁶Division of Rheumatology, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, ¹⁷Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA
Background/Purpose:C3, the central protein of the complement cascade, participates in an amplification loop that can lead to complement deposition and host tissue damage. If elevated,…
Abstract Number: 2401 • 2018 ACR/ARHP Annual Meeting
The Effects of a Gluten-Free Diet in Juvenile Idiopathic Arthritis – a Pilot Study
Anjali Sura¹, Stacey Fogarty-Brown² and Meredith Riebschleger³, ¹Pediatric Rheumatology, University of Michigan, Ann Arbor, MI, ²Pediatrics, University of Michigan, Ann Arbor, MI, ³Pediatric Rheumatology & Health Services Research, University of Michigan, Ann Arbor, MI
Background/Purpose: The caregivers of children with juvenile idiopathic arthritis (JIA) frequently ask about the utility of dietary restrictions. Some patients and physicians report a good…
Abstract Number: 2600 • 2018 ACR/ARHP Annual Meeting
Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial
Laure Gossec¹, Bruce Kirkham², Proton Rahman³, Philip Helliwell⁴, Alice B Gottlieb⁵, Wolf-Henning Boehncke⁶ and Chenglong Han⁷, ¹Rheumatology Department, Hôpital Pitié Salpêtrière, Paris 06 University, Paris, France, ²Guy's & St Thomas' NHS Foundation Trust, London, United Kingdom, ³Rheumatology, St Claires Mercy Hospital, St Johns, NF, Canada, ⁴LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁵Department of Dermatology, New York Medical College, Metropolitan Hospital, New York, NY, ⁶Department of Dermatology and Venereology, Geneva University Hospital, Geneva, Switzerland, ⁷Janssen Global Services, LLC, Malvern, PA
Background/Purpose: To evaluate the effect of guselkumab (GUS) on Health-Related Quality of Life (HRQOL) and correlate changes of HRQOL and disease activity in patients with…
Abstract Number: 2929 • 2018 ACR/ARHP Annual Meeting
Validation of Remission and Lupus Low Disease Activity State As Predictors of Organ Damage in SLE
Michelle Petri¹, Daniel Goldman¹ and Laurence S Magder², ¹Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ²Epidemiology and Public health, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Outcome measures that combine control of SLE activity and prednisone reduction are clinically relevant. A clinical goal in SLE is to reduce risk of…
Abstract Number: 300 • 2018 ACR/ARHP Annual Meeting
Built-in-Electronic-Medical-Record Disease Activity Calculators and Treat-to-Target in Rheumatoid Arthritis
Arundathi Jayatilleke¹ and Scott Pompa², ¹Department of Rheumatology, Drexel Rheumatology, Philadelphia, PA, ²Rheumatology, Drexel Rheumatology, Philadelphia, PA
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory arthritis that, if undertreated, can lead to cumulative damage and disability. The goal of treatment is to…
Abstract Number: 567 • 2018 ACR/ARHP Annual Meeting
Non-Surgical Periodontal Therapy Plus Short-Term Antibiotic Treatment May Improve Clinical Disease Activity: A Pilot Study in Difficult to Treat Rheumatoid Arthritis
Burkhard Moeller¹, Philip Bender², Sigrun Eick², Kim Midwood³, Jan Potempa⁴, Stephan Reichenbach⁵, Anja Schwenzer³, Peter M. Villiger⁶ and Alicia Wong³, ¹Rheumatology, Immunology and Allergology, Inselspital, University Hospital of Bern, Bern, Switzerland, ²School of Dental Medicine, University of Bern, Bern, Switzerland, ³Kennedy Institute for Rheumatology, Oxford University, Oxford, United Kingdom, ⁴Department of Microbiology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland, ⁵Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland, ⁶University of Bern, Bern, Switzerland
Background/Purpose: Autoimmunity against citrullinated peptides is a hallmark of rheumatoid arthritis (RA). Chronic periodontitis (CP) is a known major source of citrullinated peptides. Here, we…
Abstract Number: 1097 • 2018 ACR/ARHP Annual Meeting
Spatial-Time Cluster Analysis of SLE Disease Activity
George Stojan¹, Anton Kvit², Frank Curriero² and Michelle Petri³, ¹Division of Rheumatology, Johns Hopkins University, Baltimore, MD, ²Bloomberg School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Cluster detection is an essential tool in the public health domain with the goal of detecting anomalous clusters of disease cases. We performed a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].